Abstract
Background
The incidence of occult breast cancer among patients undergoing reduction mammoplasty or risk-reducing mastectomies ranges from 1% to approximately 10%, respectively. Identification of incidental cancer often mandates subsequent mastectomy due to ambiguous margins. This study aimed to determine the incidence of contralateral malignancy among patients undergoing oncoplastic breast-conserving surgery (OBCS) with concurrent symmetry procedures.
Methods
The authors reviewed their prospectively maintained institutional database of patients with unilateral breast cancer who underwent OBCS. Patients who underwent excisional biopsy on the contralateral breast were analyzed separately. Patient demographics, pathologic features, and subsequent disease management were evaluated.
Results
Between March 2018 and July 2022, 289 patients underwent OBCS with a symmetry procedure, and 100 patients yielded contralateral breast tissue specimens. For 14 patients, a planned excisional biopsy was performed with their symmetry procedure, and five lesions (36%) were found to be malignant. Of the remaining 86 patients, 92% underwent preoperative breast magnetic resonance imaging (MRI). Four patients (4.7%) had occult malignancies identified on the contralateral breast pathology; three patients with ductal carcinoma in situ and one patient with invasive lobular carcinoma. Three patients had undergone preoperative MRI without suspicious findings. No patients required mastectomy for treatment of the contralateral breast cancer.
Conclusion
The incidence of occult malignancy among OBCS symmetry procedures approaches 5%. The final pathology of excisional biopsies had a higher upgrade rate than previously reported. All identified malignancies were early-stage disease. The higher incidence of occult breast cancer in this population warrants the routine orientation of all specimens, which allows patients with incidental early-stage cancer the option of breast preservation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cook IS, Fuller CE. Does histopathological examination of breast reduction specimens affect patient management and clinical follow up? J Clin Pathol. 2004;57:286–9.
Freedman BC, et al. Incidence of occult carcinoma and high-risk lesions in mammaplasty specimens. Int J Breast Cancer. 2012;2012:145630.
Goodwin JT, et al. The management of incidental findings of reduction mammoplasty specimens. Can J Plast Surg. 2013;21:226–8.
Tang R, et al. Incidental breast carcinoma: incidence, management, and outcomes in 4804 bilateral reduction mammoplasties. Breast Cancer Res Treat. 2019;177:741–8.
Waldner M, et al. Occurrence of occult malignancies in reduction mammoplasties. Front Surg. 2018;5:17.
Yamauchi H, et al. High rate of occult cancer found in prophylactic mastectomy specimens despite thorough presurgical assessment with MRI and ultrasound: findings from the Hereditary Breast and Ovarian Cancer Registration 2016 in Japan. Breast Cancer Res Treat. 2018;172:679–87.
Fitzpatrick SE, Lam TC. Occult breast carcinoma is more common in women undergoing breast reduction after contralateral cancer: a systematic review and meta-analysis. Plast Reconstr Surg. 2020;146:117e-e126.
Carlson GW. The management of breast cancer detected by reduction mammaplasty. Clin Plast Surg. 2016;43:341–7.
Martin TA, et al. Outcomes of margin reexcision after oncoplastic breast reduction. Plast Reconstr Surg Glob Open. 2022;10:e4509.
Huynh V, et al. Early trajectories of patient reported outcomes in breast cancer patients undergoing lumpectomy versus mastectomy. Ann Surg Oncol. 2021;28:5677–85.
Jay M, Creelman B, Baliski C. Patient-reported outcomes associated with surgical intervention for breast cancer. Am J Surg. 2020;219:816–22.
de Boniface J, Szulkin R, Johansson ALV. Survival after breast conservation vs mastectomy adjusted for comorbidity and socioeconomic status: a Swedish national 6-year follow-up of 48 986 women. JAMA Surg. 2021;156:628–37.
Horo AG, et al. Mammoplasty for symmetry in breast reconstruction and histologic assessment. Can J Surg. 2011;54:201–5.
Wong SM, et al. Incidence of occult breast cancer in carriers of BRCA1/2 or other high-penetrance pathogenic variants undergoing prophylactic mastectomy: when is sentinel lymph node biopsy indicated? Ann Surg Oncol. 2022;29:6660–8.
Pinder SE, Thompson AM, Wesserling J. Low-risk DCIS: what is it? Observe or excise? Virchows Arch. 2022;480:21–32.
Nash AL, Hwang ES. The landmark series: ductal carcinoma in situ: the evolution of treatment. Ann Surg Oncol. 2023;30:3206–14.
Boughey JC, et al. Local recurrence after breast-conserving therapy in patients with multiple ipsilateral breast cancer: results from ACOSOG Z11102 (Alliance). J Clin Oncol. 2023;41:3184–93.
De Lorenzi F, et al. Oncoplastic breast-conserving surgery for synchronous multicentric and multifocal tumors: is it oncologically safe? A retrospective matched-cohort analysis. Ann Surg Oncol. 2022;29:427–36.
Boetes C, et al. False-negative MR imaging of malignant breast tumors. Eur Radiol. 1997;7:1231–4.
Lehman CD. Magnetic resonance imaging in the evaluation of ductal carcinoma in situ. J Natl Cancer Inst Monogr. 2010;2010:150–1.
Kuhl CK, et al. MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet. 2007;370:485–92.
Allen A, et al. Evaluating the frequency of upgrade to malignancy following surgical excision of high-risk breast lesions and ductal carcinoma in situ identified by core needle biopsy. Breast J. 2019;25:103–6.
Margenthaler JA, et al. Correlation between core biopsy and excisional biopsy in breast high-risk lesions. Am J Surg. 2006;192:534–7.
Menes TS, et al. Upgrade of high-risk breast lesions detected on mammography in the Breast Cancer Surveillance Consortium. Am J Surg. 2014;207:24–31.
Mooney KL, Bassett LW, Apple SK. Upgrade rates of high-risk breast lesions diagnosed on core needle biopsy: a single-institution experience and literature review. Mod Pathol. 2016;29:1471–84.
Kupsik M, Perez C, Bargaje A. Upstaging papillary lesions to carcinoma on surgical excision is not impacted by patient race. Breast Dis. 2019;38:67–72.
Tatarian T, et al. Intraductal papilloma with benign pathology on breast core biopsy: to excise or not? Ann Surg Oncol. 2016;23:2501–7.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
There are no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Jackson, K.M., Millen, JC., Orozco, J.I.J. et al. A Look at the Other Side: High-Risk Lesions and Occult Contralateral Malignancy in Symmetry Procedures for Patients Undergoing Oncoplastic Breast-Conserving Surgery. Ann Surg Oncol 30, 6159–6166 (2023). https://doi.org/10.1245/s10434-023-13894-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-023-13894-6